Shortage Prevention & Supply Continuity
Preventing and managing supply failure: demand and supply signals, critical material identification, scenarios, allocation, alternatives, regulatory notification and recovery. Drug shortages are a patient-harm event and increasingly a reportable one. Most trace back to a single manufacturing site or a single upstream supplier, which means they are visible on a network map long before they happen — if anyone is reading it that way.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 23 LINKSA shortage is a patient-safety event that arrives through the supply chain, and its warning signs are usually visible internally — in yield, in inventory cover, in a single ageing line — months before anyone outside notices.
06 · QUALITY MATURITY — SHORTAGE PREVENTION & SUPPLY CONTINUITY, REACTIVE TO ADAPTIVE
A shortage is discovered when orders cannot be filled. Notification is prepared under pressure after the fact.
Inventory cover is monitored and reported, but the signals that precede a shortage — yield decline, rising rejects, equipment age — are held by different functions.
Vulnerability is assessed per product against demand, capacity and single points of failure, and internal warning signals are brought together where someone can act on them.
Mitigations are prepared before they are needed — qualified alternatives, safety stock sized to real lead times — and notification obligations are known per market.
Continuity is a design property of the network, so a disruption is managed within the supply rather than announced to the market.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 5
Derived from the 5 standards SPEQ maps to this subject, across 4 regulatory bodies: FDA, ICH, EC, ISO.
RECORDS & OBJECTIVE EVIDENCE
- Vulnerability assessment per product, covering demand, capacity and dependencies
- Internal early-warning indicators, and where they are reviewed together
- Safety stock policy, with the lead-time and risk basis for the levels held
- Notification obligations per market, with owners
- Records of previous shortages or near-misses, and what changed afterwards
COMMON INSPECTION FINDINGS
- Shortage risk assessed commercially with no quality or capacity input
- Warning signals held in separate functions, so no one sees the pattern
- Safety stock set by convention rather than by lead time and risk
- Notification obligations unknown until a shortage occurs
- A previous shortage with no resulting change to the arrangement that caused it
Shortages are a quality event with a supply-chain mechanism
The proximate cause of most shortages is a quality or manufacturing failure — a contamination event, a facility remediation, an equipment failure, a failed batch sequence — occurring at a site with no redundancy. The supply-chain contribution is the absence of an alternative, and the quality contribution is whatever caused the interruption.
This makes shortage prevention a shared problem that is usually owned by neither function fully. Supply planning tracks inventory and lead time; quality tracks deviations and remediation. The combination — a product with thin cover, made at one site, currently running an elevated deviation rate — is the early-warning signal, and it is visible only when both views are read together.
Criticality is about the patient, not the revenue
A product’s commercial value and its clinical criticality are different things and frequently diverge: an old, low-margin, off-patent product may have no therapeutic alternative, while a high-revenue product sits in a class with several substitutes. Prioritisation driven by revenue will protect the wrong products in a constrained situation.
The classification worth maintaining is clinical: is there an alternative, how quickly could patients switch, and what is the harm if they cannot. That determines which products justify dual sourcing, safety stock and active monitoring — and it is the classification regulators apply when assessing whether an organisation managed a shortage responsibly.
Notification is a legal duty with its own timing
Both the US and the EU impose obligations to notify authorities of interruptions or discontinuations that could lead to shortage, with defined triggers and timelines. These attach to the anticipated interruption rather than to the shortage itself, which means the obligation can arise before the organisation is certain there will be a problem.
The consistent failure is delay caused by internal uncertainty — waiting until the picture is clear enough to be confident, by which point the notification is late. The workable approach is a pre-agreed internal trigger for assessing the notification obligation, based on the supply signal rather than on certainty, so that the assessment happens early even where the conclusion is that no notification is yet required.
SPEQ interpretation — allocation decided in advance, or decided badly
When supply is constrained, someone decides who gets product. Made during the event, that decision is made under pressure by whoever is available, on criteria that are ad hoc and hard to defend afterwards — and it is exactly the kind of decision that attracts scrutiny.
An allocation framework agreed in advance — the clinical criteria, who decides, how patients already on therapy are treated relative to new starts, how markets and channels are handled, and what is communicated — turns that into an application of an agreed policy. It cannot be written well during a shortage, and it is one of the few continuity artefacts that has a direct patient-safety justification rather than a commercial one.
FREQUENTLY ASKED
What actually causes drug shortages?
Most often a quality or manufacturing failure at a site with no redundancy — contamination, remediation, equipment failure, a failed batch sequence. Quality supplies the interruption and the supply chain supplies the absence of an alternative, which is why prevention needs both views read together rather than either alone.
How should product criticality be classified?
Clinically, not commercially. An old low-margin product may have no therapeutic alternative while a high-revenue one sits in a crowded class. Whether an alternative exists, how quickly patients could switch, and the harm if they cannot is the classification that should drive dual sourcing, safety stock and monitoring — and it is what regulators apply.
When does the notification obligation arise?
On the anticipated interruption, not on the confirmed shortage — so it can arise before the organisation is certain there is a problem. The recurring failure is waiting for certainty. A pre-agreed internal trigger based on the supply signal makes the assessment happen early even when the conclusion is that no notification is yet due.
Why write an allocation framework in advance?
Because during a shortage the decision gets made under pressure by whoever is available, on ad hoc criteria that are hard to defend. Agreeing the clinical criteria, the decision-maker, the treatment of existing patients versus new starts, and the communications in advance converts it into applying a policy — and it cannot be written well during the event.